Singapore markets closed
  • Straits Times Index

    -26.98 (-0.81%)
  • Nikkei

    +94.09 (+0.24%)
  • Hang Seng

    -170.85 (-0.94%)
  • FTSE 100

    -16.81 (-0.21%)
  • Bitcoin USD

    -785.22 (-1.17%)
  • CMC Crypto 200

    -13.30 (-0.94%)
  • S&P 500

    -2.14 (-0.04%)
  • Dow

    -57.94 (-0.15%)
  • Nasdaq

    +21.32 (+0.12%)
  • Gold

    +30.40 (+1.31%)
  • Crude Oil

    -0.13 (-0.17%)
  • 10-Yr Bond

    -0.0250 (-0.59%)
  • FTSE Bursa Malaysia

    -2.85 (-0.18%)
  • Jakarta Composite Index

    -96.73 (-1.42%)
  • PSE Index

    -7.13 (-0.11%)

Alnylam Issues 2023 Corporate Responsibility Report

– Highlighted New Disclosures of Company’s Impact on the Environment—Including Multiyear Data on Greenhouse Gas (GHG) Emissions, Energy, Water, and Waste Management Footprint–

– Expanded Alnylam Challengers Global Health Equity Initiative –

CAMBRIDGE, Mass., May 07, 2024--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2023 Corporate Responsibility Report. The company continues to take meaningful steps across each of its six corporate responsibility pillars. This year’s edition expands data disclosures across each pillar and highlights examples of the company’s commitment to ensuring patient access, reducing health inequities, and being a responsible steward of the environment.


"As we grow and progress in our quest to realize the promise of RNAi, we continue to expand our leadership and impact as a responsible corporate citizen. I am proud of the broad range of initiatives highlighted in this report, which reflect our efforts to continually increase the value that we contribute to society," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam.

Key highlights from the 2023 report include:

  • Published new data on Alnylam’s environmental impact.
    Disclosed and third-party verified multiyear data on scope 1, scope 2, and select scope 3 GHG emissions. Published multiyear data on energy, water and waste management footprint.

  • Expanded partnerships and strategies to support diversity and inclusion within clinical trials.
    Joined the Novartis-led Beacon of Hope Initiative, a ten-year collaboration with Historically Black Colleges and Universities (HBCUs) to address root causes of health disparities. Activated strategies to reach underserved communities by developing culturally appropriate clinical trial materials, training clinical trial staff, and improving plain language summaries.

  • Extended reach of Alnylam Challengers global health equity initiative.
    Grew signature social impact program to include 5 countries in which Alnylam has a local presence. Highlighted programmatic impact of partnerships with innovative social entrepreneurs and non-profit organizations working on the frontlines to address health and economic inequalities.

  • Shared new employee demographic data and results of pay equity analysis.
    Released new employee demographic data and highlighted results of a recent annual pay equity analysis.

To learn more about corporate responsibility at Alnylam, download the full 2023 Corporate Responsibility Report here.

About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.

View source version on


Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom
(Investors and Media)

Josh Brodsky